Search Results - "Dahl, Erika S."

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    Ataxia-Telangiectasia Mutated Modulation of Carbon Metabolism in Cancer by Dahl, Erika S, Aird, Katherine M

    Published in Frontiers in oncology (29-11-2017)
    “…The ataxia-telangiectasia mutated (ATM) protein kinase has been extensively studied for its role in the DNA damage response and its association with the…”
    Get full text
    Journal Article
  2. 2

    ATM inhibition drives metabolic adaptation via induction of macropinocytosis by Huang, Zhentai, Chen, Chi-Wei, Buj, Raquel, Tangudu, Naveen Kumar, Fang, Richard S, Leon, Kelly E, Dahl, Erika S, Varner, Erika L, von Krusenstiern, Eliana, Cole, Aidan R, Snyder, Nathaniel W, Aird, Katherine M

    Published in The Journal of cell biology (02-01-2023)
    “…Macropinocytosis is a nonspecific endocytic process that may enhance cancer cell survival under nutrient-poor conditions. Ataxia-Telangiectasia mutated (ATM)…”
    Get full text
    Journal Article
  3. 3

    ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells by Chen, Chi-Wei, Buj, Raquel, Dahl, Erika S., Leon, Kelly E., Aird, Katherine M.

    Published in Heliyon (01-09-2020)
    “…While therapies targeting deficiencies in the homologous recombination (HR) pathway are emerging as the standard treatment for high grade serous ovarian cancer…”
    Get full text
    Journal Article
  4. 4

    DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A by Leon, Kelly E, Buj, Raquel, Lesko, Elizabeth, Dahl, Erika S, Chen, Chi-Wei, Tangudu, Naveen Kumar, Imamura-Kawasawa, Yuka, Kossenkov, Andrew V, Hobbs, Ryan P, Aird, Katherine M

    Published in The Journal of cell biology (02-08-2021)
    “…Oncogene-induced senescence (OIS) is a stable cell cycle arrest that occurs in normal cells upon oncogene activation. Cells undergoing OIS express a wide…”
    Get full text
    Journal Article
  5. 5

    Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer by Dahl, Erika S, Buj, Raquel, Leon, Kelly E, Newell, Jordan M, Imamura, Yuka, Bitler, Benjamin G, Snyder, Nathaniel W, Aird, Katherine M

    Published in Molecular cancer research (01-08-2019)
    “…Epithelial ovarian cancer (EOC) is the deadliest gynecologic cancer. High-grade serous carcinoma (HGSC) is the most frequently diagnosed and lethal…”
    Get full text
    Journal Article
  6. 6

    Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers by Aronson, Matthew R., Dahl, Erika S., Halle, Jacob A., Simonson, Andrew W., Gogal, Rose A., Glick, Adam B., Aird, Katherine M., Medina, Scott H.

    Published in Cellular and molecular bioengineering (01-10-2020)
    “…Introduction Bacteria and cancer cells share a common trait—both possess an electronegative surface that distinguishes them from healthy mammalian…”
    Get full text
    Journal Article
  7. 7

    Abstract GMM-022: IDH1 IS A PRO-SENESCENT THERAPY IN HIGH-GRADE SEROUS OVARIAN CANCER by Dahl, Erika S, Snyder, Nathaniel W, Aird, Katherine M

    Published in Clinical cancer research (15-11-2019)
    “…Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. High-grade serous carcinoma (HGSC) is the most frequently diagnosed and fatal…”
    Get full text
    Journal Article
  8. 8

    Abstract A38: ATM inhibitor synergizes with glycolysis inhibition in ovarian cancer cells by Chen, Chi-Wei, Dahl, Erika S., Leon, Kelly E., Buj, Raquel, Aird, Katherine M.

    Published in Clinical cancer research (01-07-2020)
    “…Epithelial ovarian cancer (EOC) is the deadliest gynecologic malignancy in the USA. While therapies such as inhibitors against poly (ADP-Ribose) polymerase…”
    Get full text
    Journal Article
  9. 9

    Abstract A35: Targeting the IDH1-mediated metabolic-epigenetic axis in cyclin E-high ovarian cancer by Dahl, Erika S., Buj, Raquel, Jia, Qingyuan, Leon, Kelly E., Aird, Katherine M.

    Published in Clinical cancer research (01-07-2020)
    “…Cyclin E is an oncogene that is overexpressed in approximately 20% of high-grade serous ovarian carcinomas (HGSOC) and is associated with worse survival and…”
    Get full text
    Journal Article
  10. 10

    Abstract 1378: Targeting the metabolic-epigenetic axis to sensitize HR-proficient ovarian cancer to PARP inhibitors by Dahl, Erika S., Leon, Kelly E., Chen, Chi-Wei, Jia, Qingyuan, Buj, Raquel, Snyder, Nathaniel W., Aird, Katherine M.

    Published in Cancer research (Chicago, Ill.) (15-08-2020)
    “…Overexpression of the oncogene cyclin E1 is considered one of the initiating factors in fallopian tube transformation and ovarian tumorigenesis. Patients with…”
    Get full text
    Journal Article
  11. 11

    Targeting IDH1 as a pro-senescent therapy in high-grade serous ovarian cancer by Dahl, Erika S., Buj, Raquel, Leon, Kelly E., Newell, Jordan M., Imamura, Yuka, Bitler, Benjamin G., Snyder, Nathaniel W., Aird, Katherine M.

    Published in Molecular cancer research (20-05-2019)
    “…Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer. High-grade serous carcinoma (HGSC) is the most frequently diagnosed and lethal…”
    Get full text
    Journal Article